On November 11, 2020, CR Medicon and Predicine jointly announced that it has entered into a global strategic partnership to assist biomarker-driven clinical trials and novel oncology therapeutics registration in US and China.
Predicine, a Hayward, Calif.-based precision medicine company, today announced it has completed its $13.5M Series A financing from Sangel Capital, Rongsheng Investment, and Highlight Capital.